Safety and Preliminary Effectiveness of the BaroSense Articulating Circular Endoscopic (ACE) Stapler for Plication of Dilated Post-surgical Gastric Anatomy

NCT ID: NCT01388673

Last Updated: 2012-02-08

Basic Information

• Recruitment Status: WITHDRAWN
• Clinical Phase: NA
• Study Classification: INTERVENTIONAL
• Study Start Date: 2011-10-31
• Study Completion Date: 2013-02-28

Brief Summary

The BaroSense Articulating Circular Endoscopic (ACE) Stapler is an investigational instrument indicated for endoluminal trans-oral tissue approximation and ligation in the gastrointestinal tract. This study explores the specific application of tissue apposition in dilated post-surgical gastric anatomy such as observed in a dilated Roux-en-Y Gastric Bypass (RYGB) pouch.

The primary objective of this study is to perform an evaluation of the safety of the ACE Stapler for the treatment of dilated post-surgical gastric anatomy.

The secondary objective of this study is to evaluate the preliminary efficacy of the ACE Stapler for the treatment of dilated post-surgical gastric anatomy over a 12 month follow-up period.

Conditions

Obese

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

ACE Stapler procedure

ACE Stapler procedure for the treatment of dilated post-surgical gastric anatomy

Group Type: EXPERIMENTAL

BaroSense ACE Stapler for plication of dilated post-surgical gastric anatomy

Intervention Type: PROCEDURE

The ACE Stapler is used endoscopically, an incorporates a unique tissue capture mechanism to produce large, permanent serosa to serosa plications in a completely trans-oral approach.

Interventions

BaroSense ACE Stapler for plication of dilated post-surgical gastric anatomy

The ACE Stapler is used endoscopically, an incorporates a unique tissue capture mechanism to produce large, permanent serosa to serosa plications in a completely trans-oral approach.

Intervention Type: PROCEDURE

Eligibility Criteria

Inclusion Criteria

1. Subject, male or female, is age 18 to 60 years of age.

2. Subject must be able to understand and be willing to sign an informed consent document.

3. Subject must be willing and able to participate in all aspects of the study and agree to comply with all study requirements for the duration of the study. This includes availability of reliable transportation and sufficient time to attend all follow-up visits.

4. Subject must be > 2 years post RYGB surgery.

5. Subject must have documented records indicating an initial achievement of > 60% EWL (based on an ideal weight of 25 BMI) at some point after RYGB surgery.

6. Subject has a BMI at baseline of > 30 and < 50.

7. At time of enrollment, subject must have regained at least 35% of the maximum weight lost following RYGB, and the weight regain must have occurred over a period of not less than 3 months from the point of maximum weight loss.

8. Subject must have a stoma diameter of at least 18 mm.

9. Subject must be fully ambulatory, without chronic reliance on walking aids such as crutches, walkers or a wheelchair.

Exclusion Criteria

1. Subject has a severe eating disorder.

2. Investigator determines that there is another causal factor for the subject's weight regain other than dilated gastric anatomy.

3. Subject has previously undergone an endoscopic or surgical repair of dilated pouch or stoma (including sclerotherapy treatments).

4. Subject had irreversible or life threatening complications following initial RYGB procedure (cardio or respiratory).

5. Subject has an ongoing severe complication from their initial RYGB procedure (recurrent ventral hernia, pain syndrome, etc.).

6. Subject has an intragastric fistula, anastomotic leak, or staple/suture line disruption.

7. Subject has history of/or signs and/or symptoms of gastro-duodenal ulcer disease.

8. Subject has symptomatic congestive heart failure, cardiac arrhythmia or unstable coronary artery disease.

9. Subject has pre-existing respiratory disease such as chronic obstructive pulmonary disease (COPD), pneumonia or cancer.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 60 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

BaroSense Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Other Identifiers

Protocol 11-02

Identifier Type: -

Identifier Source: org_study_id